Wow. Not sure, but that sounds like a fine shareholder derivative suit.
Since it was the company's patent lawyers mistake, I was expecting a malpractice suit. Maybe no suit was filed because MDCO has not yet lost anything and they all wait for generic versions of Angiomax to enter the market.